Drug intelligence / Profile preview

Osurnia

Development stage
Unknown
Lead developer
Dechra
Modality
Small Molecules
Administration
Topical (otic)
01

Overview

Osurnia is a veterinary topical gel formulation containing three active ingredients—**florfenicol** (an antibacterial), **terbinafine** (an antifungal), and **betamethasone acetate** (a corticosteroid with anti-inflammatory activity)[2][4][5][7][8]. It is indicated **for the treatment of otitis externa in dogs**, specifically where infections are associated with susceptible strains of *Staphylococcus pseudintermedius* (bacteria) and *Malassezia pachydermatis* (yeast)[2][4][7][8]. Florfenicol acts as a bacteriostatic antibiotic by inhibiting protein synthesis in susceptible bacteria. Terbinafine is an allylamine antifungal that selectively inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membranes. Betamethasone acetate exerts anti-inflammatory effects by binding to glucocorticoid receptors, reducing swelling, itching, and discomfort in infected ear tissue. Osurnia is administered as a gel instilled directly into the dog's ear canal in a two-dose regimen (seven days apart), to maintain therapeutic concentrations at the infection site for up to 45 days[1][5][7].

Brand names
Osurnia
Other names
florfenicol + terbinafine + betamethasone acetate otic gel
02

Targets

NeuraminidaseSQLE (Squalene monooxygenase)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Osurnia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osurnia.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call